Newsroom | 5271 results

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced fourth quarter and full year 2025 financial results and provided a business update. “The launch of our second-generation Swoop® scanner, our Optive AI™ software, and the addition of a new market in the neurology office setting in...

BOSTON--(BUSINESS WIRE)--Nia Theraputics' Smart Neurostimulation System is the first neurostimulation device to receive Breakthrough designation for TBI-related memory loss...

SAN FRANCISCO--(BUSINESS WIRE)--Mave Health, a neurotech company, announced $2.1 million in seed funding led by Blume Ventures with participation from other funds and angel investors, including Stanford Angels, Dhaval Shroff, and Raymond Russell. The company recently launched a non-invasive wearable headset built to improve focus, elevate mood, and regulate stress in just 20 minutes a day. Mave debuted with over 500 beta customers ahead of its public release last month. Based on self-reported d...

MANHASSET, N.Y.--(BUSINESS WIRE)--For patients living with Systemic Lupus Erythematosus (SLE), their immune systems mistakenly attack themselves, unleashing dangerous and painful levels of inflammation. For many, the goal is to reach remission, when symptoms disappear. While remission often means an end to obvious symptoms, scientists are exploring if it signifies complete healing, or if underlying issues, particularly in the brain, might still be “simmering” unnoticed. To study this, scientist...

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the publication of a research study led by Dr. Alireza Faridar and Dr. Stanley Appel at the Houston Methodist Neurological Institute, demonstrating the involvement of the peripheral immune system in the neuroinflammatory profile of frontotemporal dementia (FTD). The study has been published in the pee...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the Canadian Intellectual Property Office has registered five of the Company’s trademarks, including its house marks, Enveric and Enveric Biosciences. “The registration of a Company’s house marks, such as our marks Enveric and Enveric Bioscie...

NASHVILLE, Tenn.--(BUSINESS WIRE)--PhaseWell Research (“PhaseWell”), a multisite clinical research company, today announced the strategic acquisition of Chase Medical Research (“CMR”). Under the leadership of founder, key opinion leader, and lead Principal Investigator Dr. Joseph Soufer, CMR operates sites in Waterbury and Hamden, Connecticut. The partnership supports PhaseWell’s mission of connecting communities to clinical trials, bringing hope today and shaping tomorrow’s medicine. Headquart...

PHILADELPHIA--(BUSINESS WIRE)--iECURE, Inc., a clinical-stage genome editing company developing variant-agnostic in vivo targeted gene insertion therapies for the treatment of severe, inherited, neurometabolic disorders, today announced that the U.S. Food and Drug Administration (FDA) has selected ECUR-506, the company’s investigational in vivo targeted gene insertion therapy for neonatal-onset ornithine transcarbamylase (OTC) deficiency, to participate in the Chemistry, Manufacturing, and Cont...

BARCELONA, Spain--(BUSINESS WIRE)--Ferrer has been recognised by Ethisphere, a global leader in defining and advancing standards of ethical business practices, as one of the World’s Most Ethical Companies® 2026. Ferrer is the only Spanish pharmaceutical company to receive this recognition in 2026. This year, only 138 organisations worldwide, from 17 countries and 40 different industries, have achieved this distinction. One of the most prestigious international rankings, it recognizes organisati...

GALWAY, Ireland--(BUSINESS WIRE)--Perfuze, a medical device company dedicated to advancing stroke treatment through next-generation catheter technology, today announced it has received FDA 510(k) clearance for the Millipede88® Aspiration Catheter. The clearance follows the successful completion of the MARRS (Millipede AspiRation for Revascularization in Stroke) clinical study, which met all primary objectives, and positions Perfuze as a leader in the super-bore aspiration segment, the fastest-g...